Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--th...
Gespeichert in:
| Veröffentlicht in: | BMJ 2010, Vol.341 (7774), p.c5396 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7774 |
| container_start_page | c5396 |
| container_title | BMJ |
| container_volume | 341 |
| creator | Desser, Arna S Gyrd-Hansen, Dorte Olsen, Jan Abel Grepperud, Sverre Kristiansen, Ivar Sønbø |
| description | Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--those targeting diseases with very low prevalence--often fail to meet standard cost effectiveness thresholds for public reimbursement. Debate about exempting orphan drugs from such criteria centers on whether a societal preference for rarity exists. |
| doi_str_mv | 10.1136/bmj.c5396 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1907026568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2164382661</sourcerecordid><originalsourceid>FETCH-LOGICAL-b276t-558d86abef2c23c26935a3261cc555145b1c8e7ac20394542101418749a745113</originalsourceid><addsrcrecordid>eNp10EtPAjEUBeDGaCJBFv6DRt24GOxjbh_uDCoaCSaKxl1TSsFBoNgOIP_eAYw7Vnfz5eSeg9ApJU1KubjqT8dNB1yLA1SjuVAZKM4PUY1o0JmiXB2jRkpjQgjjUmkBNfTyGlzhSzvBy8KvEg4zHOL8087wIC5G6Rq7GFLCybuyCLOKpUVc-jUOQ9wNceVHhZ0lbEd-gHOCy4CFPEFHQztJvvF36-jt_q7Xesg6z-3H1k0n6zMpygxADZSwfT9kjnHHhOZgORPUOQCgOfSpU15axwjXOeSMEppTJXNtZQ5V3zo62-XOY_he-FSacVjE6sdkJCjBiKS6Quf7ENVEEiZAqEpd7tS2bfRDM4_F1Ma1ocRspjXVtGY7bWWznS1S6X_-oY1fRkguwXTfW6bNafu29wTmo_IXO7-J2B_7C7ZJg0k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1907026568</pqid></control><display><type>article</type><title>Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Jstor Complete Legacy</source><source>BMJ Journals - NESLi2</source><creator>Desser, Arna S ; Gyrd-Hansen, Dorte ; Olsen, Jan Abel ; Grepperud, Sverre ; Kristiansen, Ivar Sønbø</creator><creatorcontrib>Desser, Arna S ; Gyrd-Hansen, Dorte ; Olsen, Jan Abel ; Grepperud, Sverre ; Kristiansen, Ivar Sønbø</creatorcontrib><description>Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--those targeting diseases with very low prevalence--often fail to meet standard cost effectiveness thresholds for public reimbursement. Debate about exempting orphan drugs from such criteria centers on whether a societal preference for rarity exists.</description><edition>International edition</edition><identifier>ISSN: 0959-8138</identifier><identifier>ISSN: 0959-8146</identifier><identifier>EISSN: 1468-5833</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.c5396</identifier><identifier>CODEN: BMJOAE</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Disease ; Drugs ; Medical treatment ; R&D ; Research & development ; Studies</subject><ispartof>BMJ, 2010, Vol.341 (7774), p.c5396</ispartof><rights>BMJ Publishing Group Ltd 2010</rights><rights>Copyright: 2010 (c) BMJ Publishing Group Ltd 2010</rights><rights>Copyright BMJ Publishing Group Sep 25, 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bmj.com/content/341/bmj.c5396.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bmj.com/content/341/bmj.c5396.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,4010,23550,27900,27901,27902,30976,77343,77374</link.rule.ids></links><search><creatorcontrib>Desser, Arna S</creatorcontrib><creatorcontrib>Gyrd-Hansen, Dorte</creatorcontrib><creatorcontrib>Olsen, Jan Abel</creatorcontrib><creatorcontrib>Grepperud, Sverre</creatorcontrib><creatorcontrib>Kristiansen, Ivar Sønbø</creatorcontrib><title>Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67</title><title>BMJ</title><addtitle>BMJ</addtitle><description>Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--those targeting diseases with very low prevalence--often fail to meet standard cost effectiveness thresholds for public reimbursement. Debate about exempting orphan drugs from such criteria centers on whether a societal preference for rarity exists.</description><subject>Disease</subject><subject>Drugs</subject><subject>Medical treatment</subject><subject>R&D</subject><subject>Research & development</subject><subject>Studies</subject><issn>0959-8138</issn><issn>0959-8146</issn><issn>1468-5833</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>7QJ</sourceid><recordid>eNp10EtPAjEUBeDGaCJBFv6DRt24GOxjbh_uDCoaCSaKxl1TSsFBoNgOIP_eAYw7Vnfz5eSeg9ApJU1KubjqT8dNB1yLA1SjuVAZKM4PUY1o0JmiXB2jRkpjQgjjUmkBNfTyGlzhSzvBy8KvEg4zHOL8087wIC5G6Rq7GFLCybuyCLOKpUVc-jUOQ9wNceVHhZ0lbEd-gHOCy4CFPEFHQztJvvF36-jt_q7Xesg6z-3H1k0n6zMpygxADZSwfT9kjnHHhOZgORPUOQCgOfSpU15axwjXOeSMEppTJXNtZQ5V3zo62-XOY_he-FSacVjE6sdkJCjBiKS6Quf7ENVEEiZAqEpd7tS2bfRDM4_F1Ma1ocRspjXVtGY7bWWznS1S6X_-oY1fRkguwXTfW6bNafu29wTmo_IXO7-J2B_7C7ZJg0k</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Desser, Arna S</creator><creator>Gyrd-Hansen, Dorte</creator><creator>Olsen, Jan Abel</creator><creator>Grepperud, Sverre</creator><creator>Kristiansen, Ivar Sønbø</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QJ</scope></search><sort><creationdate>2010</creationdate><title>Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67</title><author>Desser, Arna S ; Gyrd-Hansen, Dorte ; Olsen, Jan Abel ; Grepperud, Sverre ; Kristiansen, Ivar Sønbø</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b276t-558d86abef2c23c26935a3261cc555145b1c8e7ac20394542101418749a745113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Disease</topic><topic>Drugs</topic><topic>Medical treatment</topic><topic>R&D</topic><topic>Research & development</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Desser, Arna S</creatorcontrib><creatorcontrib>Gyrd-Hansen, Dorte</creatorcontrib><creatorcontrib>Olsen, Jan Abel</creatorcontrib><creatorcontrib>Grepperud, Sverre</creatorcontrib><creatorcontrib>Kristiansen, Ivar Sønbø</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Desser, Arna S</au><au>Gyrd-Hansen, Dorte</au><au>Olsen, Jan Abel</au><au>Grepperud, Sverre</au><au>Kristiansen, Ivar Sønbø</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>2010</date><risdate>2010</risdate><volume>341</volume><issue>7774</issue><spage>c5396</spage><pages>c5396-</pages><issn>0959-8138</issn><issn>0959-8146</issn><eissn>1468-5833</eissn><eissn>1756-1833</eissn><coden>BMJOAE</coden><abstract>Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--those targeting diseases with very low prevalence--often fail to meet standard cost effectiveness thresholds for public reimbursement. Debate about exempting orphan drugs from such criteria centers on whether a societal preference for rarity exists.</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/bmj.c5396</doi><edition>International edition</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8138 |
| ispartof | BMJ, 2010, Vol.341 (7774), p.c5396 |
| issn | 0959-8138 0959-8146 1468-5833 1756-1833 |
| language | eng |
| recordid | cdi_proquest_journals_1907026568 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Jstor Complete Legacy; BMJ Journals - NESLi2 |
| subjects | Disease Drugs Medical treatment R&D Research & development Studies |
| title | Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A07%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Societal%20views%20on%20orphan%20drugs:%20cross%20sectional%20survey%20of%20Norwegians%20aged%2040%20to%2067&rft.jtitle=BMJ&rft.au=Desser,%20Arna%20S&rft.date=2010&rft.volume=341&rft.issue=7774&rft.spage=c5396&rft.pages=c5396-&rft.issn=0959-8138&rft.eissn=1468-5833&rft.coden=BMJOAE&rft_id=info:doi/10.1136/bmj.c5396&rft_dat=%3Cproquest_cross%3E2164382661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1907026568&rft_id=info:pmid/&rfr_iscdi=true |